Eli Lilly signs oncology research partnership with Stipple Bio carrying up to $5.9 billion in potential milestones

Eli Lilly has entered a multi-target oncology research collaboration with Stipple Bio carrying up to $5.9 billion in potential milestone payments, centred on the discovery of tumour-specific therapeutic targets.
Stipple Bio announced on 16 November 2026 that it had signed a research collaboration and licensing agreement granting Eli Lilly exclusive worldwide rights to develop and commercialise products arising from Stipple's Pointillist tumour-specific epitope discovery platform across multiple oncology targets and therapeutic modalities.
Stipple will receive an undisclosed upfront payment and equity investment and may earn up to $5.9 billion in research, development and commercial milestone payments alongside tiered royalties; the agreement is a discovery and licensing partnership rather than an acquisition, and the headline milestone value is contingent on future achievements.
Field | Content |
Partner One | Eli Lilly |
Partner Two | Stipple Bio |
Announcement Date | 16 November 2026 |
Agreement Type | Multi-target research collaboration and licensing |
Therapeutic Area | Oncology |
Technology Platform | Pointillist |
Platform Focus | Discovery of tumour-specific epitopes |
Research Scope | Multiple oncology targets and therapeutic modalities |
Licensed Rights | Exclusive worldwide development and commercialisation rights to resulting products |
Upfront Payment | Undisclosed |
Equity Investment | Included; amount undisclosed |
Potential Milestone Payments | Up to $5.9 billion |
Milestone Categories | Research development and commercial |
Additional Consideration | Tiered royalties |
Financial Conditions | Most headline value is contingent on future milestones |
Strategic Significance | Supports discovery of precision oncology medicines targeting tumour-specific biology |
Primary Source | https://stipple.bio/stipple-bio-announces-multi-target-multi-modality-oncology-research-collaboration-with-lilly/ |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com

Comentarios